Travere legal chief sells 37.5K shares

Travere Therapeutics’ Chief Legal Officer exercised 37,500 options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) reported that its Chief Legal Officer and General Counsel, Elizabeth E. Reed, exercised 37,500 stock options for common shares at an exercise price of $15.46 per share on September 15, 2026, then sold 37,500 common shares in multiple open-market transactions the same day. The option was fully vested and exercisable, and the sales were made pursuant to a written trading plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c).

Insider Trade Summary 10b5-1

Exercise and Sale: 37,500 shares ($1.76M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider REED ELIZABETH E

Role Chief Legal Officer and GC

Sold 37,500 shs ($2.34M)

Approx. gross sale proceeds $2.34M

Approx. exercise cost $580K

Approx. pre-tax spread $1.76M

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) F6	37,500	$0.00	$0.00
Exercise	Common Stock F1	37,500	$15.46	$580K
Sale	Common Stock F2, F3	21,926	$62.0255	$1.36M
Sale	Common Stock F2, F4	13,874	$62.6326	$869K
Sale	Common Stock F2, F5	1,400	$63.6902	$89K
Sale	Common Stock F2	300	$65.31	$20K

Holdings After Transaction: Employee stock option (right to buy) — 0 contracts (Direct); Common Stock — 105,389 shares (Direct)

Footnotes (6)

1. F1. Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
2. F2. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
3. F3. The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
5. F5. The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
6. F6. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 37,500 shares Option exercise price: $15.46 per share Shares sold same day: 37,500 shares +5 more

8 metrics

Options exercised 37,500 shares Stock options for Travere Therapeutics common stock exercised on September 15, 2026

Option exercise price $15.46 per share Exercise price of employee stock option converted into common shares

Shares sold same day 37,500 shares Total common shares sold in open-market transactions on September 15, 2026

Sale block 21,926 shares at $62.0255 Common stock sale with weighted average price and price range $61.44–$62.42

Sale block 13,874 shares at $62.6326 Common stock sale with weighted average price and price range $62.44–$63.31

Sale block 1,400 shares at $63.6902 Common stock sale with weighted average price and price range $63.59–$63.85

Additional sale block 300 shares at $65.31 Additional open-market sale of common stock on September 15, 2026

ESPP shares included 178 shares Shares acquired under the 2017 Employee Stock Purchase Plan on May 29, 2026 included in holdings

Key Terms

Rule 10b5-1(c), weighted average sale price, Employee Stock Purchase Plan, fully vested and exercisable

4 terms

Rule 10b5-1(c) regulatory

"plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $62.0255"

Employee Stock Purchase Plan financial

"Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

fully vested and exercisable financial

"The stock option is fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TVTX report for Elizabeth E. Reed?

Elizabeth E. Reed exercised 37,500 stock options for Travere Therapeutics common shares at $15.46 per share on September 15, 2026 and sold 37,500 common shares in several same-day open-market transactions.

Were the September 15, 2026 TVTX insider sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were made pursuant to a written plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

What prices did the Travere Therapeutics (TVTX) insider receive for the sold shares?

The reported sales of common stock on September 15, 2026 covered 37,500 shares at weighted average prices of $62.0255, $62.6326, and $63.6902, with individual trades ranging between $61.44 and $63.85 per share.

How many Travere Therapeutics (TVTX) stock options did the insider exercise?

Elizabeth E. Reed exercised 37,500 stock options for Travere Therapeutics common stock on September 15, 2026, at an exercise price of $15.46 per share. A related note explains that this stock option was fully vested and exercisable.

Did the Travere Therapeutics insider acquire any shares through an employee stock purchase plan?

Yes. A note explains that the holdings reported include 178 shares acquired under Travere Therapeutics’ 2017 Employee Stock Purchase Plan on May 29, 2026, as part of the insider’s common stock position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:33 PM Accepted by SEC EDGAR 09/17/2026 - 09:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REED ELIZABETH E

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer and GC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		37,500	A	$15.46	142,889(1)	D
Common Stock	09/15/2026		S(2)		21,926	D	$62.0255(3)	120,963	D
Common Stock	09/15/2026		S(2)		13,874	D	$62.6326(4)	107,089	D
Common Stock	09/15/2026		S(2)		1,400	D	$63.6902(5)	105,689	D
Common Stock	09/15/2026		S(2)		300	D	$65.31	105,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$15.46	09/15/2026		M			37,500	(6)	01/31/2030	Common Stock	37,500	$0	0	D

Explanation of Responses:

1. Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.

2. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

3. The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

6. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)